文献速递膀胱癌与上尿路尿路上皮癌

高危非肌层浸润性膀胱癌卡介苗膀胱灌注与即刻根治性膀胱切除术的结局比较

Outcomes of BCG vs upfront radical cystectomy for high-risk non-muscle-invasive bladder cancer.
PubMed 文献 · BJU Int · 2025-02-18

基于欧洲多中心数据库2015至2024年1491例高危或极高危非肌层浸润性膀胱癌患者的回顾性分析,比较即刻根治性膀胱切除术与至少五剂卡介苗膀胱灌注的肿瘤学结局。倾向性评分匹配后,两组5年癌症特异性死亡率相似(卡介苗组13% vs 即刻根治性膀胱切除术组16%,风险比1.77,95%CI 0.66-4.73,P=0.3)。卡介苗组中6.6%最终需延迟根治性膀胱切除术,进展前手术者3年癌症特异性死亡率与即刻手术相当,进展后手术者结局更差。

要点

  • 匹配后卡介苗灌注与即刻根治性膀胱切除术的5年癌症特异性死亡率相似(13% vs 16%,P=0.3)。
  • 初始卡介苗组中6.6%需延迟根治性膀胱切除术,其中47%在延迟手术前已进展为肌层浸润性膀胱癌。
  • 进展前行延迟根治性膀胱切除术者3年癌症特异性死亡率与即刻手术相当,进展后手术者结局更差。

核心结论

  • 在欧洲高危和极高危非肌层浸润性膀胱癌队列中,即刻根治性膀胱切除术极少施行,接受卡介苗灌注的患者相对即刻根治性膀胱切除术患者未表现出癌症特异性死亡劣势。
  • 匹配后卡介苗治疗与即刻根治性膀胱切除术的长期癌症特异性死亡率相似。
  • 延迟根治性膀胱切除术若在进展后施行则结局更差,若在进展前施行则与即刻根治性膀胱切除术相当,凸显及时手术的重要性。

研究设计与样本

  • 回顾性分析欧洲多中心数据库2015至2024年诊断的1491例高危或极高危非肌层浸润性膀胱癌患者。
  • 纳入接受即刻根治性膀胱切除术或至少五剂卡介苗灌注的患者,按临床相关变量进行1:1倾向性评分匹配。
  • 进展定义为肌层浸润性疾病或转移性疾病,采用累积发生率图和竞争风险回归模型分析癌症特异性死亡率。

主要发现

  • 1221例高危或极高危患者中,87例(7.1%)接受即刻根治性膀胱切除术,中位随访2.6年。
  • 倾向性评分匹配后(87例 vs 87例),卡介苗组5年癌症特异性死亡率为13%,即刻根治性膀胱切除术组为16%(风险比1.77,95%CI 0.66-4.73;P=0.3)。
  • 1134例初始接受卡介苗治疗的患者中,73例(6.6%)最终需要延迟根治性膀胱切除术,其中34例(47%)在延迟手术前进展为肌层浸润性膀胱癌。
  • 在未进展患者中,即刻根治性膀胱切除术与延迟根治性膀胱切除术的3年癌症特异性死亡率相当(13% vs 11%,P=0.3)。
  • 延迟根治性膀胱切除术前者中,进展患者相对未进展患者3年癌症特异性死亡率更差(13% vs 31%,风险比0.32,95%CI 0.13-0.83;P=0.018)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the oncological outcomes of patients with high-risk (HR) and very high-risk (VHR) non-muscle-invasive bladder cancer (NMIBC) treated with upfront radical cystectomy (RC) vs Bacillus Calmette-Guérin (BCG) instillations from a contemporary European multicentre cohort. PATIENTS AND METHODS: We conducted a retrospective analysis of 1491 patients diagnosed with HR- or VHR-NMIBC from a European multicentre database between 2015 and 2024. Patients were included if they received either upfront RC or at least five doses of BCG. A 1:1 propensity score matching (PSM) according to clinically relevant variables was applied. Progression was defined as muscle-invasive or metastatic disease. Cumulative incidence plots and multivariable competing risk regression models addressing cancer-specific mortality (CSM) were fitted. RESULTS: Among the 1221 patients with HR- (n = 1221 [90%]) or VHR-NMIBC (n = 121 [10%]), 87 (7.1%) underwent upfront RC. The median follow-up was 2.6 years. After PSM (87 vs 87 patients), the 5-year CSM rate was similar in patients treated with BCG (13%) vs their upfront RC counterparts (16%) (hazard ratio: 1.77, 95% confidence interval [CI] 0.66-4.73; P = 0.3). Of the 1134 patients who initially received BCG, 73 (6.6%) eventually required delayed RC, with 34 (47%) progressing to muscle-invasive bladder cancer before delayed RC. The 3-year CSM rate was comparable in upfront RC (13%) vs delayed RC (11%) among non-progressing patients (P = 0.3). However, patients who progressed before delayed RC had worse 3-year CSM relative to those who did not (13% vs 31%, hazard ratio: 0.32, 95% CI 0.13-0.83; P = 0.018). CONCLUSION: Within a European cohort of patients with HR- and VHR-NMIBC, upfront RC was rarely performed. Patients treated with BCG did not exhibit a CSM disadvantage relative to their upfront RC counterparts. After matching, long-term CSM was similar between BCG therapy and upfront RC. Delayed RC, led to worse outcomes if performed after progression, but matched upfront RC when performed before progression, underscoring importance of timely surgery.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Scilipoti P, Longoni M, de Angelis M, et al. Outcomes of BCG vs upfront radical cystectomy for high-risk non-muscle-invasive bladder cancer. BJU Int. 2025. PMID: 39967051. doi:10.1111/bju.16675

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。